These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

600 related items for PubMed ID: 24599275

  • 1. Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months.
    Anastasilakis AD, Polyzos SA, Makras P, Gkiomisi A, Bisbinas I, Katsarou A, Filippaios A, Mantzoros CS.
    Osteoporos Int; 2014 May; 25(5):1633-42. PubMed ID: 24599275
    [Abstract] [Full Text] [Related]

  • 2. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.
    Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E.
    Osteoporos Int; 2012 Mar; 23(3):1171-6. PubMed ID: 21305266
    [Abstract] [Full Text] [Related]

  • 3. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
    Brown JP, Roux C, Ho PR, Bolognese MA, Hall J, Bone HG, Bonnick S, van den Bergh JP, Ferreira I, Dakin P, Wagman RB, Recknor C.
    Osteoporos Int; 2014 Jul; 25(7):1953-61. PubMed ID: 24676847
    [Abstract] [Full Text] [Related]

  • 4. Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis.
    Ebina K, Hirao M, Hashimoto J, Hagihara K, Kashii M, Kitaguchi K, Matsuoka H, Iwahashi T, Chijimatsu R, Yoshikawa H.
    J Bone Miner Metab; 2018 Jul; 36(4):478-487. PubMed ID: 28766140
    [Abstract] [Full Text] [Related]

  • 5. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study.
    Zanchetta MB, Boailchuk J, Massari F, Silveira F, Bogado C, Zanchetta JR.
    Osteoporos Int; 2018 Jan; 29(1):41-47. PubMed ID: 28975362
    [Abstract] [Full Text] [Related]

  • 6. Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial.
    Leder BZ, Tsai JN, Neer RM, Uihlein AV, Wallace PM, Burnett-Bowie SA.
    J Clin Densitom; 2016 Jan; 19(3):346-51. PubMed ID: 26900146
    [Abstract] [Full Text] [Related]

  • 7. The impact of switching once-weekly teriparatide to denosumab in osteoporosis patients.
    Miyagi M, Fujimaki H, Naruse K, Suto K, Inoue G, Nakazawa T, Imura T, Saito W, Uchida K, Shirasawa E, Takahira N, Takaso M.
    J Orthop Sci; 2019 Jan; 24(1):153-158. PubMed ID: 30146385
    [Abstract] [Full Text] [Related]

  • 8. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
    Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA.
    Lancet; 2015 Sep 19; 386(9999):1147-55. PubMed ID: 26144908
    [Abstract] [Full Text] [Related]

  • 9. Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass.
    Anastasilakis AD, Polyzos SA, Makras P, Rauner M, Sonnleitner L, Hawa G, Tsourdi E, Yavropoulou MP, Missbichler A, Terpos E.
    J Musculoskelet Neuronal Interact; 2019 Sep 01; 19(3):253-257. PubMed ID: 31475931
    [Abstract] [Full Text] [Related]

  • 10. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.
    J Bone Miner Res; 2011 Mar 01; 26(3):503-11. PubMed ID: 20814967
    [Abstract] [Full Text] [Related]

  • 11. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.
    Leder BZ, Tsai JN, Uihlein AV, Burnett-Bowie SA, Zhu Y, Foley K, Lee H, Neer RM.
    J Clin Endocrinol Metab; 2014 May 01; 99(5):1694-700. PubMed ID: 24517156
    [Abstract] [Full Text] [Related]

  • 12. Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment.
    Anastasilakis AD, Polyzos SA, Makras P, Gkiomisi A, Sakellariou G, Savvidis M, Papatheodorou A, Kokkoris P, Terpos E.
    Expert Opin Ther Targets; 2015 Mar 01; 19(3):299-306. PubMed ID: 25395071
    [Abstract] [Full Text] [Related]

  • 13. Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study.
    Silverman SL, Siris E, Kendler DL, Belazi D, Brown JP, Gold DT, Lewiecki EM, Papaioannou A, Simonelli C, Ferreira I, Balasubramanian A, Dakin P, Ho P, Siddhanti S, Stolshek B, Recknor C.
    Osteoporos Int; 2015 Jan 01; 26(1):361-72. PubMed ID: 25236877
    [Abstract] [Full Text] [Related]

  • 14. Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis.
    Ebina K, Etani Y, Tsuboi H, Nagayama Y, Kashii M, Miyama A, Kunugiza Y, Hirao M, Okamura G, Noguchi T, Takami K, Goshima A, Miura T, Fukuda Y, Kurihara T, Okada S, Nakata K.
    Osteoporos Int; 2022 Aug 01; 33(8):1807-1813. PubMed ID: 35362725
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The combined effect of Parathyroid hormone (1-34) and whole-body Vibration exercise in the treatment of postmenopausal OSteoporosis (PaVOS study): a randomized controlled trial.
    Jepsen DB, Ryg J, Hansen S, Jørgensen NR, Gram J, Masud T.
    Osteoporos Int; 2019 Sep 01; 30(9):1827-1836. PubMed ID: 31309239
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients.
    Ebina K, Hashimoto J, Shi K, Kashii M, Hirao M, Yoshikawa H.
    Osteoporos Int; 2014 Dec 01; 25(12):2755-65. PubMed ID: 25082556
    [Abstract] [Full Text] [Related]

  • 19. Effect of Teriparatide Treatment on Circulating Periostin and Its Relationship to Regulators of Bone Formation and BMD in Postmenopausal Women With Osteoporosis.
    Gossiel F, Scott JR, Paggiosi MA, Naylor KE, McCloskey EV, Peel NFA, Walsh JS, Eastell R.
    J Clin Endocrinol Metab; 2018 Apr 01; 103(4):1302-1309. PubMed ID: 29365099
    [Abstract] [Full Text] [Related]

  • 20. Serum parathyroid hormone is associated with increased cortical porosity of the inner transitional zone at the proximal femur in postmenopausal women: the Tromsø Study.
    Osima M, Borgen TT, Lukic M, Grimnes G, Joakimsen RM, Eriksen EF, Bjørnerem Å.
    Osteoporos Int; 2018 Feb 01; 29(2):421-431. PubMed ID: 29134242
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.